EVEREST MED (01952) obtained the director and major shareholder's purchase of over HK$38 million in shares.

Everest MED (01952) announced that on December 12, 2025, Mr. Fu Wei (Non-executive Director, Honorary Chairman of the Board of Directors and major shareholder of the company), Mr. Wu Yifang (Executive Director and Chairman of the Board of Directors), Mr. Luo Yongqing (Executive Director and Chief Executive Officer of the company), and Mr. He Ying (Executive Director, President and Chief Financial Officer of the company) respectively acquired 339,000 shares, 277,000 shares, 132,500 shares and 98,200 shares of the company's common stock in the market, with a total consideration exceeding HK$38 million, at an average price of approximately HK$45.01 per share. The company was informed that, subject to market conditions and within the limits of applicable laws and regulations, Cambridge Capital (as the major shareholder of the company) has further committed to increasing its shareholding by no more than 1% within the next three to six months. The Board believes that the voluntary share purchases by the directors and the commitment made by Cambridge Capital demonstrate a strong confidence in the company's future prospects and long-term development.